Quick Answer
Xeris Biopharma Holdings, Inc. reported Operating Income Loss of $24.90 million for the year ending 2025.
- Xeris Biopharma Holdings, Inc. showed an increase of +174.0% in Operating Income Loss from 2024 to 2025.
- This data is from Xeris Biopharma Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Xeris Biopharma Holdings, Inc.'s Operating Income Loss has grown by 129.8%.
- Historical annual values: Fiscal year 2025: $24.90 million | Fiscal year 2024: -$33.65 million | Fiscal year 2023: -$44.01 million | Fiscal year 2022: -$81.94 million | Fiscal year 2021: -$115.16 million | Fiscal year 2020: -$83.55 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: